These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26182797)

  • 1. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
    Kieran J; Bennett K; Coghlan M; Bergin C; Barry M
    Ir Med J; 2015 Jun; 108(6):166-9. PubMed ID: 26182797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience with chronic hepatitis C in Northern Ireland: epidemiology and response to monotherapy.
    McDougall NI; McCluggage WG; Coyle PV; Sloan JM; Callender ME
    Ulster Med J; 2004 May; 73(1):25-31. PubMed ID: 15244122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
    Younossi Z; Henry L
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
    Haj-Ali Saflo O; Hernández Guijo JM
    Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doing battle with HCV.
    Fimmel CJ
    Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
    [No Abstract]   [Full Text] [Related]  

  • 11. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
    Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
    Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?
    Lagging M; Alsiö S; Hellstrand K; Norkrans G;
    J Hepatol; 2011 Apr; 54(4):835-6; author reply 836-7. PubMed ID: 21145838
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis C in elderly patients.
    Horsmans Y
    Expert Opin Pharmacother; 2010 Mar; 11(4):571-7. PubMed ID: 20163268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
    Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
    J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL.
    Saag MS
    Clin Infect Dis; 2015 Jul; 61(2):169-70. PubMed ID: 25778748
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis C drug therapy update].
    Ruano Camps R; Gallego Fernández C
    Farm Hosp; 2003; 27(6):371-85. PubMed ID: 14974883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.